Print

Noven Pharmaceuticals Inc. (NOVN) Announces Commencement of Phase 2 Study of Investigational d-Amphetamine Transdermal System for ADHD  
10/2/2012 10:18:14 AM

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD.